Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Head and Neck Cancer

Aliases
Cancer of the Head and Neck, Recurrent Head and Neck Cancer

255 clinical trials

263 products

39 drugs

Clinical trial
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
Status: Terminated, Estimated PCD: 2023-02-13
Product
NIR178
Product
Tigilanol Tiglate
Clinical trial
A Phase II, Open Label, Single Arm Study To Assess The Efficacy Of Intratumoral Tigilanol Tiglate In Various Head And Neck Solid Malignancies
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or Metastatic Head-Neck Cancer
Status: Recruiting, Estimated PCD: 2026-06-01
Product
PDR001
Product
RiMO-301
Clinical trial
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2024-12-01
Product
CDX-585
Product
CT-0508
Clinical trial
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Status: Terminated, Estimated PCD: 2023-06-02
Product
Pembrolizumab
Clinical trial
A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-08-25
Product
NT219
Clinical trial
A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Status: Recruiting, Estimated PCD: 2027-10-05
Product
Placebo
Product
Xevinapant
Product
PY159
Product
MDX2001
Clinical trial
A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-08-01
Product
NEXI-003
Clinical trial
A Phase 2 Study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Cisplatin + Carboplatin
Product
evorpacept
Product
pembrolizumab
Product
EOS-448
Clinical trial
A Multicenter, Open-Label, Phase I/II Study of EOS884448 (EOS-448) in Combination With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-09-01
Product
inupadenant
Product
Dostarlimab
Product
SOC chemotherapies
Clinical trial
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2022-09-13
Product
Chemotherapy
Product
E-602
Clinical trial
A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Terminated, Estimated PCD: 2022-07-29
Product
BDC-3042
Product
Fludarabine
Clinical trial
A Phase 1 Open-Label Dose-Escalation Study of the Safety of Adoptively Transferred Autologous CD8+ T Lymphocytes Targeting HPV-16 E6/E7, HPV-18 E6/E7 and Survivin in Patients With Relapsed or Refractory HPV-related Oropharyngeal Cancers
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Product
Enoblituzumab
Product
Retifanlimab
Product
Tebotelimab
Clinical trial
An Open-label, Dose-escalation, Phase 1 Study to Investigate the Safety and Tolerability of WM-A1-3389, in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-02-22
Clinical trial
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2026-03-01
Product
CDX-1140
Product
Cyclophosphamide
Product
WM-A1-3389
Clinical trial
A Single Arm, Open Label, Phase 1b Study of Xevinapant in Combination With Weekly Cisplatin and Intensity-modulated Radiotherapy to Assess Safety and Tolerability in Participants With LA SCCHN, Suitable for Definitive Chemoradiotherapy (HyperlynX)
Status: Recruiting, Estimated PCD: 2025-04-01
Product
APX005M
Clinical trial
A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers
Status: Recruiting, Estimated PCD: 2025-06-01
Product
CDX-301
Clinical trial
A Phase 1/2 Study With Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
Status: Active (not recruiting), Estimated PCD: 2024-05-08
Product
Cisplatin
Clinical trial
Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects With Solid Tumors
Status: Completed, Estimated PCD: 2018-06-13
Product
PY159/Pembrolizumab Combination
Product
CX-2029
Product
SOC Chemotherapies
Product
MEM-288
Product
Nivolumab
Clinical trial
A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)
Status: Completed, Estimated PCD: 2023-06-01
Product
NT219 and ERBITUX
Product
Cemiplimab
Product
PY159/Pembrolizumab
Clinical trial
A Phase 2 Study of ALX148 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase I Study of MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2025-11-01
Product
MAGE-A4ᶜ¹º³²T cells
Clinical trial
Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Immune checkpoint blockers
Product
DK210
Product
MCLA-128
Clinical trial
Treatment Plan of the HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Status:
Clinical trial
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Status: Active (not recruiting), Estimated PCD: 2022-12-27
Clinical trial
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 Mutations
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Niraparib
Clinical trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY AND PHARMACODYNAMICS OF PF-07263689, EITHER ALONE OR IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY, IN PREVIOUSLY TREATED PARTICIPANTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Status: Terminated, Estimated PCD: 2022-10-14
Product
GM103
Clinical trial
A Phase I/II, Open-label, Dose-escalation With Expansion Study of GM103 Via Intratumoral Injection, Alone and in Combination With Pembrolizumab in Adult Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-05-30
Product
GM103 and Pembrolizumab
Product
PF-07263689
Product
Sasanlimab
Clinical trial
A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Status: Active (not recruiting), Estimated PCD: 2018-07-19
Product
Cetuximab
Product
Carboplatin
Product
Epacadostat
Product
5-Fluorouracil
Clinical trial
A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Recruiting, Estimated PCD: 2024-05-21
Product
INCAGN02385
Clinical trial
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Status: Recruiting, Estimated PCD: 2025-12-23
Product
INCAGN02390
Product
COM701
Product
ADP-A2M4CD8
Product
PC14586
Clinical trial
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Status: Recruiting, Estimated PCD: 2026-03-17
Product
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
Clinical trial
A Phase 1b, Open-Label, Single-Arm Dose-Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, in Combination With Nivolumab in Patients With Primary PD-1 Inhibitor Resistant Metastatic or Locally Incurable, Recurrent HNSCC
Status: Withdrawn, Estimated PCD: 2023-04-01
Product
IK-175 + Nivolumab
Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-02-02
Product
INBRX-106
Product
PY159 Pembrolizumab
Product
BI 765049
Product
Ezabenlimab
Clinical trial
Phase I, Non-randomised, Open-label, Multi-centre Dose Escalation and Expansion Trial of BI 765049 and BI 765049 + Ezabenlimab Administered by Repeated Intravenous Infusion in Asian Patients With Malignant Solid Tumours Expressing B7-H6
Status: Recruiting, Estimated PCD: 2026-11-13
Clinical trial
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-06-01
Product
SNS-101
Product
COM701 + BMS-986207 + Nivolumab
Product
Autogene cevumeran
Product
Atezolizumab
Clinical trial
A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy With Pembrolizumab in First Line Patients With HPV16+ Recurrent/Metastatic HNSCC
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
CUE-101
Product
HER3-DXd
Clinical trial
HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
Status: Recruiting, Estimated PCD: 2025-12-30
Product
PD-1 inhibitor
Product
CAB-ROR2-ADC
Clinical trial
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
Status: Recruiting, Estimated PCD: 2025-02-01
Product
CTX-471
Product
ASP-1929
Clinical trial
A Phase 2 Single-arm Study of ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck, With or Without Metastases, Not Amenable to Curative Local Treatment
Status: Terminated, Estimated PCD: 2023-11-20
Product
LYT-200
Clinical trial
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 as a Single Agent and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Tislelizumab
Product
Gemcitabine/nab-paclitaxel
Product
PY159/Pembrolizumab Combination dose expansion cohort 6
Clinical trial
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
SYH2051
Clinical trial
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Product
NC410
Clinical trial
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Product
Sotatercept
Clinical trial
A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Status: Completed, Estimated PCD: 2020-06-16
Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
RO6874281
Clinical trial
An Open-Label, Multicenter, Dose-Escalation, Phase Ia/Ib Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-α (FAP), as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Status: Completed, Estimated PCD: 2022-11-10
Product
FT500
Product
WM-S1-030
Clinical trial
A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Completed, Estimated PCD: 2019-01-23
Product
CYT-0851
Product
Recombinant oncolytic herpes simplex virus type 1 (R130)
Product
RAPA-201
Clinical trial
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)
Status: Completed, Estimated PCD: 2022-11-15
Clinical trial
Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-08-08
Clinical trial
Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer
Status: Terminated, Estimated PCD: 2019-07-09
Product
MEDI4736
Product
Seribantumab
Clinical trial
An Open-Label Randomized, Phase 2A, Dose-Ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Terminated, Estimated PCD: 2012-09-21
Product
ADXS11-001
Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2025-03-27
Product
IL-2
Product
Ipilimumab
Clinical trial
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYH2051 Monotherapy in Patients With Advanced Solid Tumors or in Combination With Radiotherapy in Patients With Locally Advanced Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase Ib/IIa, Multicenter, Open-label Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Status: Not yet recruiting, Estimated PCD: 2026-01-25
Product
Toripalimab
Clinical trial
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2020-08-31
Clinical trial
Phase Ib/ll Clinical Study to Evaluate Safety and Dosing of Humanised Monoclonal Antibody CA9hu-1 to Human Carbonic Anhydrase IX in Patients With Advanced Solid Tumours
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Product
ILB-2109
Product
Ozuriftamab
Clinical trial
A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in PD-1/L1 Failure Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Recruiting, Estimated PCD: 2024-12-01
Product
CA9hu-1
Product
zalutumumab
Product
INCB001158
Clinical trial
An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination With Radiotherapy, in Patients With Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum Based Chemotherapy
Status: Terminated, Estimated PCD: 2010-10-01
Product
Zalutumumab
Product
BT5528
Clinical trial
A Phase 1 Study of RTX-321 for the Treatment of Patients With Advanced Malignancies Associated With Human Papillomavirus-16 Infection
Status: Terminated, Estimated PCD: 2022-11-30
Product
RTX-321
Clinical trial
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic Profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Non-curable Patients With SCCHN
Status: Completed, Estimated PCD: 2011-07-01
Product
Letrozole
Product
TumoCure
Product
PRT1419
Clinical trial
A Single Arm, Prospective, Open Label, Multi Center, Phase Ib Study to Evaluate the Safety, Tolerability and Initial Efficacy of a Single Intra-tumoral Injection of IntraGel's Polymer-based Cisplatin-loaded Gel (TumoCure) in Subjects With Progressive or Radio-resistant Primary Head and Neck Tumor
Status: Recruiting, Estimated PCD: 2023-11-15
Clinical trial
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2023-04-06
Clinical trial
A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies
Status: Completed, Estimated PCD: 2022-01-12
Product
FT536
Product
CDX-527
Product
A166
Product
CX-2009
Product
Benzydamine Hydrochloride
Clinical trial
Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2010-12-15
Clinical trial
A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-08-11
Product
Panitumumab
Product
Avelumab
Product
Amivantamab
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-02-06
Clinical trial
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)
Status: Terminated, Estimated PCD: 2020-09-10
Product
AMXT1501
Product
DFMO
Clinical trial
Phase IV Study on the Feasibility of a Preventative/Therapeutic Approach With Benzydamine Oromucosal Solution in Radiation-induced Oral Mucositis (OM) in Patients With Head and Neck Cancer (HNC)
Status: Completed, Estimated PCD: 2022-09-05
Clinical trial
An Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Best Supportive Care, in Patients With Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-based Chemotherapy.
Status: Completed, Estimated PCD: 2011-08-01
Product
QBS10072S
Clinical trial
A Phase II Clinical Study to Evaluate the Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
Status: Completed
Product
Tc 99m EC20
Clinical trial
A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma
Status: Completed, Estimated PCD: 2022-09-21
Product
Cetuximab/Erbitux
Clinical trial
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Completed, Estimated PCD: 2021-05-10
Product
cabozantinib
Product
atezolizumab
Product
CK-301
Product
KVA12123
Clinical trial
A Phase 1/2 Open-label Trial of KVA12123 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
Status: Recruiting, Estimated PCD: 2021-11-18
Product
Cisplatin/Platinol
Product
Carboplatin/Paraplatin
Product
Fluorouracil/Adrucil
Product
Ulixertinib
Clinical trial
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Status:
Product
APG-157
Clinical trial
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-07-01
Product
KVA12123 Plus Pembrolizumab
Clinical trial
The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-02-08
Clinical trial
Phase 2 Study to Evaluate the Safety and Efficacy of APG-157 as Neoadjuvant/Induction Therapy for Patients With Head and Neck Squamous Cell Cancer (HNSCC) of the Oral Cavity and/or Oropharynx
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Buparlisib & Paclitaxel
Product
TJ004309
Clinical trial
An Open, Single-armed, Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED PALBOCICLIB CLINICAL STUDIES
Status: Recruiting, Estimated PCD: 2026-04-19
Product
Palbociclib
Product
Fulvestrant
Clinical trial
A Phase I, Open-Label, Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Infused SNB-101(as SN-38) in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Product
SNB-101
Clinical trial
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
Abraxane
Drug
Cisplatin
Clinical trial
A Phase I Trial of Olaparib in Addition to Cisplatin-based Concurrent Chemoradiotherapy for Patients With High Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (NHSCC)
Status: Active (not recruiting), Estimated PCD: 2020-06-01
Product
Olaparib
Clinical trial
Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2024-05-01
Product
DEFINITY
Clinical trial
Assessment of Genomic Alterations and Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers
Status: Recruiting, Estimated PCD: 2024-06-30
Product
PCR - Immunohistochemistry - Immunolabelling
Clinical trial
A Phase Ib/II Multicenter Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Drug
pembrolizumab
Product
valemetostat
Clinical trial
Continuous Local Anesthetic Wound Infusion to Improve Quality of Recovery Following Ablative Surgery and Neck Dissection: a Randomized Controlled Trial.
Status: Not yet recruiting, Estimated PCD: 2025-08-31
Product
Lidocaine
Product
0.9% Normal Saline
Clinical trial
A Phase I/II Basket Trial Evaluating a Combination of Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumour
Status: Active (not recruiting), Estimated PCD: 2022-04-01
Product
Durvalumab + Tremelimumab + Vinorelbine
Clinical trial
A Phase I Trial of Re-Irradiation With Concurrent Chemotherapy in Combination With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase I/II Dose Escalation Study of the CDK4/6 Inhibitor, Palbociclib in Combination With Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Active (not recruiting), Estimated PCD: 2024-03-11
Product
Leucovorin calcium
Clinical trial
Multimodality Management of Head and Neck Cancer: A Phase II Trial of Induction Chemotherapy, Organ Preservation Surgery, and Concurrent Chemoradiotherapy
Status: Active (not recruiting), Estimated PCD: 2017-02-14
Product
Gene Expression Analysis
Product
Protein Expression Analysis
Clinical trial
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Active (not recruiting), Estimated PCD: 2022-11-01
Clinical trial
A Pilot Study of Neoadjuvant Cemiplimab With Platinum-Doublet Chemotherapy, and Cetuximab in Patients With Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-06-20
Drug
AN0025
Drug
Docetaxel
Clinical trial
Administration of T Cells Expressing Chondroitin-Sulfate-Proteoglycan-4 Specific Chimeric Antigen Receptors (CAR) in Subjects With Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Recruiting, Estimated PCD: 2026-08-01
Drug
cyclophosphamide
Product
Cell Therapy
Clinical trial
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
Status: Recruiting, Estimated PCD: 2026-09-01
Drug
PD-1 antibody
Clinical trial
Sequential Therapy With Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
Status: Completed, Estimated PCD: 2022-10-31
Clinical trial
A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies
Status: Completed, Estimated PCD: 2021-10-15
Clinical trial
Topical Anaesthesia in Cutaneous Head and Neck Surgery: a Randomized Controlled Trial
Status: Completed, Estimated PCD: 2023-07-07
Product
EMLA
Clinical trial
Phase II Study of First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Randomized, Placebo-Controlled, Phase 2 Study Of Induction Chemotherapy With Cisplatin/Carboplatin, And Docetaxel With Or Without Erlotinib In Patients With Head And Neck Squamous Cell Carcinomas Amenable For Surgical Resection
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
Erlotinib
Clinical trial
A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer
Status: Withdrawn, Estimated PCD: 2026-08-01
Product
Venlafaxine
Clinical trial
Single and Combined Modality Trans-Oral Robotic Surgery in Early Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence: The SCORE Study
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Molecular Analysis
Clinical trial
A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients in Remission to Reduce Recurrence Regardless of HPV Status
Status: Active (not recruiting), Estimated PCD: 2025-04-06
Product
PepCan
Clinical trial
A Phase II Trial of Xevinapant in Combination With Post-Operative Cisplatin and Radiotherapy for High Risk Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2026-11-01
Product
Xevinapan
Clinical trial
A Phase IB Rescue Study With Oral Decitabine (AStX727) and Durvalumab (MEDI4736) Combination Therapy in Recurrent and/or Metastatic Head and Neck Cancer Patients Who Have Progressed on Anti-PD-1, Anti-PD-L1, or Anti-CTLA-4 Monotherapy
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
Decitabine
Product
Durvalumab
Clinical trial
Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation
Status: Completed, Estimated PCD: 2021-10-12
Product
Methotrexate
Clinical trial
Real-time Margin Assessment in Head and Neck Cancer - Enhancing Specificity by Combining Fresh Frozen Sectioning With Targeted Fluorescence Imaging
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Cetuximab-IRDye800
Clinical trial
Early Phase I Window of Opportunity Biomarker and Safety Trial to Test Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated, Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-04-15
Product
Pyrimethamine
Clinical trial
A Phase I/II Study of Dermaprazole For Radiation Dermatitis in Post-Mastectomy Breast Cancer and Head and Neck Cancer Patients.
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Dermaprazole
Clinical trial
Smoking Cessation Treatment for Head & Neck Cancer Patients: Acceptance and Commitment Therapy
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Product
Varenicline
Clinical trial
Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With Radiotherapy
Status: Completed, Estimated PCD: 2022-10-01
Product
Ialuset®
Clinical trial
A Pilot Window of Opportunity Study of Imatinib in Combination With Cetuximab in Patients With Squamous Cell Carcinomas of the Head and Neck
Status: Recruiting, Estimated PCD: 2025-09-01
Product
Imatinib
Clinical trial
A Randomized, Double-blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence - the PATHWay Study.
Status: Active (not recruiting), Estimated PCD: 2025-06-20
Drug
Varlilumab
Clinical trial
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Gedatolisib
Clinical trial
Pathological Response Adapted Decision-making of Postoperative Management for HNSCC Receiving Induction Immunotherapy and Chemotherapy
Status: Recruiting, Estimated PCD: 2025-12-30
Product
Anti-PD-1 or PD-L1 Antibody
Clinical trial
Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
Status: , Estimated PCD: 2018-07-12
Drug
cetuximab
Product
cisplatin
Clinical trial
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2017-09-17
Product
Anti-OX40 antibody
Clinical trial
Phase II Trial of Post-operative or Definitive Concurrent Radiation and Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2022-01-19
Clinical trial
Multimodality Risk Adapted Therapy Including Carboplatin/Paclitaxel/Lapatinib as Induction for Squamous Cell Carcinoma of the Head and Neck Amenable to Transoral Surgical Approaches
Status: Active (not recruiting), Estimated PCD: 2016-11-01
Drug
Tiragolumab
Product
Lapatinib
Clinical trial
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
Status: Recruiting, Estimated PCD: 2027-12-31
Product
Pegsitacianine
Clinical trial
A Phase 2 Study of Preoperative Pembrolizumab and Chemotherapy Followed by Adjuvant Pembrolizumab in Resectable Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-05-20
Drug
mFOLFOX6
Product
CISPLATIN
Clinical trial
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-30
Product
TSC-204-A0101
Product
TSC-204-A0201
Product
TSC-204-C0702
Product
TSC-200-A0201 + TSC-204-A0101
Product
TSC-200-A0201 + TSC-201-B0702
Product
TSC-203-A0201 + TSC-201-B0702
Clinical trial
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
Status: Recruiting, Estimated PCD: 2027-08-01
Product
Molecular Analyses
Clinical trial
Multimodal Management for Perioperative Analgesia in Otolaryngology - Head and Neck Free Flap Reconstructive Surgery: A Prospective Study
Status: Completed, Estimated PCD: 2021-06-01
Product
Tylenol
Product
Oxycodone
Product
Morphine
Product
Gabapentin
Product
toradol
Product
Bupivacaine
Clinical trial
Effectiveness of Topical Morphine Use in Patients With Painful Neoplastic Wounds in the Breast and Head and Neck: Double Blind Randomized Clinical Trial - MorphineGEL
Status: Recruiting, Estimated PCD: 2024-03-01
Product
Morphine Sulfate
Product
Lidocaine Hcl 2% Jelly
Clinical trial
Exploratory Study of Early Biomarkers Allowing Dynamic Assessment of Response to Treatment in Cancers of the Head and Neck
Status: Recruiting, Estimated PCD: 2026-04-01
Product
Circulating tumour DNA dynamics
Clinical trial
A Phase III Trial of Concurrent Radiation and Chemotherapy for Advanced Head and Neck Carcinomas
Status: Completed, Estimated PCD: 2010-06-01
Clinical trial
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2022-04-05
Clinical trial
Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer
Status: Completed, Estimated PCD: 1999-01-15
Product
13-cis retinoic acid
Clinical trial
Phase III Randomized Trial of Methotrexate vs. Paclitaxel in Cisplatin-Ineligible Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2000-08-01
Drug
methotrexate
Drug
paclitaxel
Clinical trial
A Phase II Study of Pembrolizumab in Combination With Circulating Tumor DNA Response-Adaptive Pulsed Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: The SINERGY Trial (Squamous Cell Carcinoma of Head and Neck Response-Guided Therapy)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2022-03-29
Drug
Atezolizumab
Clinical trial
CLINICAL EFFICACY OF MOLECULAR ANALYSIS OF SURGICAL MARGINS AND REGIONAL LYMPH NODES IN MANAGEMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA
Status: Completed, Estimated PCD: 2002-10-18
Product
DNA stability
Product
Microsatellite Instability Analysis
Product
Mutation analysis
Clinical trial
A Phase II Trial OF Chemoradiation For Organ Preservation In Resectable Stage III or IV Squamous Cell Carcinomas Of The Larynx Or Oropharynx
Status: Completed, Estimated PCD: 2007-03-01
Drug
carboplatin
Clinical trial
Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy
Status: Completed, Estimated PCD: 2017-01-25
Product
5-Fluorouracile
Clinical trial
A Phase 0 Open Label, Single-center Clinical Trial of ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Operable Head and Neck Cancer.
Status: Completed, Estimated PCD: 2020-12-18
Product
ABY-029
Clinical trial
Phase II Trial Of Weekly Irinotecan And Docetaxel In Recurrent Or Metastatic Head And Neck Carcinoma
Status: Completed, Estimated PCD: 2005-04-01
Drug
docetaxel
Product
Irinotecan
Clinical trial
Phase Ib Study of Pembrolizumab in Combination With Chemo Radiotherapy (CRT) for Locally-advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Active (not recruiting), Estimated PCD: 2020-09-29
Clinical trial
Multicenter Randomized Controlled Phase III Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
Adjuvant Nivolumab and Ipilimumab
Clinical trial
A Window of Opportunity Trial of Cetuximab in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Completed, Estimated PCD: 2022-03-15
Clinical trial
Clinical Effect Of Application Of Jeksung Combined With Anti-radiation Spray In Patients Radiotherapy-Induced Oral Mucositis Of Local Advanced Head And Neck Tumors
Status: Completed, Estimated PCD: 2022-08-31
Product
Jeksung
Clinical trial
Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Effectiveness of Thyme Honey in Management of Xerostomia in Post Radiation Cancer Patients A Randomized Controlled Clinical Trial With a Biochemical Assessment
Status: Completed, Estimated PCD: 2021-06-20
Product
Thyme Honey Mouth Rinse
Product
Saline Mouth Rinse
Clinical trial
Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment
Status: Completed, Estimated PCD: 2023-02-28
Clinical trial
PHASE II TRIAL OF TAXOL IN ADVANCED OR METASTATIC SALIVARY GLAND MALIGNANCIES
Status: , Estimated PCD: 2002-05-01
Clinical trial
Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI, PEP02, MM-398, Onivyde®) With 5-FU and Leucovorin in Squamous Cell Carcinoma (SCC) of Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy
Status: Completed, Estimated PCD: 2022-12-31
Drug
nanoliposomal irinotecan
Clinical trial
A Phase II Study of Docetaxel, Carboplatin With and Without Low Dose Radiation as Induction Therapy in Locally Advanced Head and Neck Cancer
Status: Completed, Estimated PCD: 2018-03-01
Product
Docetaxel and Carboplatin
Clinical trial
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Drug
T-VEC
Clinical trial
Randomized, Double Blind, Placebo Controlled Phase III Evaluation of Cisplatin + Placebo Versus Cisplatin + C225 a Mouse/Human Monoclonal Antibody to the Epidermal Growth Factor Receptor, in Patients With Metastatic and/or Recurrent Squamous Cell Cancer of the Head and Neck
Status: , Estimated PCD: 2004-09-01
Clinical trial
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Checkpoint Blockade Immune
Clinical trial
An Investigation of Postoperative Pain, Why Still in Hospital and Days Alive and Out of Hospital Following Transoral Robotic Surgery for Squamous Cell Carcinoma of Unknown Primary and Obstructive Sleep Apnea
Status: Completed, Estimated PCD: 2022-11-09
Drug
lenalidomide
Clinical trial
A Phase II Trial of Induction Chemotherapy Followed by Cetuximab (Erbitux) With Low Dose vs. Standard Dose IMRT in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx
Status: Completed, Estimated PCD: 2015-01-01
Clinical trial
A Randomized Phase II Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers
Status: Terminated, Estimated PCD: 2021-11-24
Clinical trial
Triplex CTLA4/PD1/PDL1 Checkpoint Inhibitors Combination Therapy for Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-10-30
Product
Ipilimumab + Pembrolizumab + Durvalumab
Clinical trial
A Phase I Study of Xevinapant With Radiation and Concurrent Carboplatin and Paclitaxel in Patients Ineligible for Cisplatin With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Active (not recruiting), Estimated PCD: 2027-10-01
Clinical trial
An Open-label, Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity
Status: Withdrawn, Estimated PCD: 2025-05-01
Product
Ketamine
Drug
Pamiparib
Drug
hydroxyurea
Product
Fluorouracil
Clinical trial
Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery
Status: Recruiting, Estimated PCD: 2026-05-01
Product
Indocyanine green
Drug
fluorouracil
Product
Gemcitabine
Clinical trial
Therapeutic Combination of CLR 131 With External Beam Radiation in Head and Neck Cancer
Status: Active (not recruiting), Estimated PCD: 2022-09-19
Product
CLR 131
Clinical trial
Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Not Eligible for Cisplatin Therapy
Status: Completed, Estimated PCD: 2019-12-23
Clinical trial
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Status: Active (not recruiting), Estimated PCD: 2026-10-31
Clinical trial
A Phase 2 Trial of PD-L1 t-haNK, N-803 IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505)
Status: Recruiting, Estimated PCD: 2025-07-31
Product
PD-L1 t-haNK
Drug
N-803
Clinical trial
A Pilot Study of Radiation De-Escalation for p16 Negative Oropharyngeal Cancer and p16-Negative or Positive Laryngeal and Hypopharyngeal Cancers
Status: Recruiting, Estimated PCD: 2027-03-12
Clinical trial
Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Recruiting, Estimated PCD: 2024-06-30
Product
Clopidogrel
Drug
Aspirin
Clinical trial
A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients
Status: Completed, Estimated PCD: 2019-10-04
Product
DPX-E7
Clinical trial
Preoperative Immune Checkpoint Inhibitor Therapy for Patients With Primary Untreated or Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)
Status: Completed, Estimated PCD: 2023-10-17
Clinical trial
Phase II Trial of Definitive Chemoradiation With Elective Nodal Irradiation Dose De-escalation for p16 Positive Squamous Cell Carcinoma of the Oropharynx "ENID"
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO]
Status: Active (not recruiting), Estimated PCD: 2011-06-01
Product
Recombinant thyroid-stimulating hormone
Product
Ethyl chloride
Product
Aqueous cream
Clinical trial
Pilot Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer
Status: , Estimated PCD: 2025-03-01
Product
111I-n Panitumumab
Clinical trial
Pilot Study of Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
Status: Terminated, Estimated PCD: 2024-01-31
Product
Adnectin 18F-BMS-986192
Clinical trial
Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck
Status: , Estimated PCD: 2025-02-28
Product
Near-infrared fluorescence lymphatic imaging
Clinical trial
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2027-01-01
Product
BGB-A425
Drug
LBL-007
Clinical trial
Serotonin-Norepinephrine Reuptake Inhibitors for the Prevention and Treatment of Pain, Depression, and Anxiety in Patients With Head & Neck Cancer
Status: Not yet recruiting, Estimated PCD: 2026-09-01
Product
Paclitaxel
Clinical trial
A Pilot Study to Assess the Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2022-10-31
Product
ribavirin
Clinical trial
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx
Status: Withdrawn, Estimated PCD: 2023-07-25
Product
SAR444245
Clinical trial
Phase II Clinical Trial of the Combination of RAD001 and Erlotinib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2014-11-01
Product
RAD001
Clinical trial
Neoadjuvant Tislelizumab With Afatinib for the Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial (neoCHANCE-1 Trial)
Status: Recruiting, Estimated PCD: 2023-08-19
Product
Afatinib
Clinical trial
Comparison of Every 3 Week Versus Weekly Cisplatin Concurrent With Radiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Correlation With Oxidative Stress Markers
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
An Open-label, Phase II Study of Durvalumab (MEDI4736) in Combination With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
PD-1 Immune Checkpoint Inhibition for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers With or Without a History of Lung Cancer
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2029-08-25
Product
Immunotherapy
Clinical trial
An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2017-11-10
Product
Veliparib
Clinical trial
Phase I/II Trial of Gabapentin Plus Ketamine for Prevention and Treatment of Acute and Chronic Pain in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation
Status: Recruiting, Estimated PCD: 2025-12-31
Drug
Ketamine
Clinical trial
Armodafinil for Persistent Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer: a Randomized Phase II Study
Status: Completed, Estimated PCD: 2022-12-08
Product
Armodafinil
Clinical trial
Opioid Therapy vs Multimodal Analgesia in Head and Neck Cancer: A Randomized Clinical Trial
Status: Completed, Estimated PCD: 2023-09-15
Product
Opioids
Product
PAiN
Clinical trial
Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With SCCHN
Status: Completed, Estimated PCD: 2018-09-11
Clinical trial
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
Status: Recruiting, Estimated PCD: 2027-01-11
Clinical trial
Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Xerostomia After Radiation Therapy for Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2026-03-31
Product
MSC
Clinical trial
DARTBOARD: A Prospective Randomized Phase II Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-15
Clinical trial
CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors: CHEERS-trial
Status: Completed, Estimated PCD: 2022-02-01
Clinical trial
A Single Arm Phase 2 Study of Adjuvant Nivolumab After Salvage Resection in Head and Neck Squamous Cell Carcinoma Patients Previously Treated With Definitive Therapy
Status: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta Trap (M7824 ) Alone and in Combination With TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection.
Status: Completed, Estimated PCD: 2021-08-24
Product
M7824
Product
N803
Clinical trial
Phase II Interventional Study Using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2028-08-01
Drug
Atorvastatin
Clinical trial
Phase I Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck
Status: Active (not recruiting), Estimated PCD: 2021-01-01
Clinical trial
Phase II Open-Label Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Panitumumab-IRDye800
Clinical trial
A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2004-08-01
Product
ZD1839
Product
TriAd
Clinical trial
A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors
Status: Completed, Estimated PCD: 2008-09-29
Product
TSC-203-A0201
Product
TSC-201-B0702
Product
TSC-204-A0201 + TSC-204-A0101
Clinical trial
The Effect of Curcuma Long Oral Gel in Relation to Salivary Epidermal Growth Factor & Interleukin-8 on Radiation Induced Oral Mucositis in Iraqi Cancer Patients
Status: Completed, Estimated PCD: 2023-03-01
Product
Curcumin
Product
Standard Preparation
Clinical trial
Prognostic Markers for a Better Follow-up in Head and Neck Cancer.
Status: Recruiting, Estimated PCD: 2024-05-31
Product
DNA exome sequencing
Clinical trial
A Phase II Study of Induction Chemotherapy Followed by Surgical Treatment in Locally Advanced Oropharyngeal And Supraglotic Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-12-30
Clinical trial
Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
Status: Terminated, Estimated PCD: 2023-02-07
Product
64Cu-DOTA-ECL1i
Clinical trial
A Phase II Clinical Trial of Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer Patients (CTMS# 20-0147)
Status: Recruiting, Estimated PCD: 2027-09-30
Product
Aquaphor
Clinical trial
Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy
Status: Active (not recruiting), Estimated PCD: 2027-02-02
Product
Barium
Clinical trial
A Phase III Study of Standard Fractionation Radiotherapy With Concurrent High-Dose Cisplatin Versus Accelerated Fractionation Radiotherapy With Panitumumab in Patients With Locally Advanced Stage III and IV Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2015-05-16
Drug
panitumumab
Clinical trial
Phase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy With Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-03-25
Clinical trial
Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase I Study of Adjuvant OSI-774 (Tarceva®) in Patients Following Combined Chemo-Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2008-12-09
Product
Erlotinib
Clinical trial
Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings
Status: , Estimated PCD: 2002-02-01
Product
nicotine
Clinical trial
Pilot Study of Tissue and Hematopoietic/Mesenchymal Stem Cell Collection for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
Status: Active (not recruiting), Estimated PCD: 2018-07-06
Drug
Filgrastim
Clinical trial
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
MEDI0562
Clinical trial
Phase II Evaluation of Paclitaxel Infusion in Advanced (Recurrent or Metastatic) Squamous Cell Carcinoma of the Head and Neck
Status: , Estimated PCD: 2001-09-01
Clinical trial
Induction by Docetaxel/Cisplatin/5-Fluorouracil (TCF) Prior to Radiotherapy With Concomintant Cetuximab in Locally Advanced Inoperable Head and Neck Tumours - a Methodical Trial
Status: Completed, Estimated PCD: 2010-01-19
Clinical trial
A Phase II Trial of Carboplatin Plus Paclitaxel in the Treatment of Locally Recurrent or Metastatic Nasopharyngeal Carcinoma
Status: , Estimated PCD: 2001-07-01
Clinical trial
A Multi-Institutional, Open-Label, Randomized, Phase II Trial Of Ibrutinib In Combination With EGFR Inhibition Or PD-1 Inhibition In Patients With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-01-11
Product
Ibrutinib
Clinical trial
EACH: A Randomised Phase II Study Evaluating the Safety and Anti-tumour Activity of the Combination of Avelumab and Cetuximab Relative to Avelumab Monotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Cancer
Status: Active (not recruiting), Estimated PCD: 2021-09-15
Clinical trial
Phase III Randomized Study of Adjuvant Biologic Therapy in Patients With Stages III/IV Head and Neck Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2004-12-01
Product
Recombinant Interferon Alfa
Drug
isotretinoin
Clinical trial
Ph II Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
Status: Completed, Estimated PCD: 2018-07-01
Product
ZD 1839
Clinical trial
Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.
Status: Recruiting, Estimated PCD: 2026-01-01
Product
Capsaicin patch
Product
Amitriptyline
Product
Ficlatuzumab
Clinical trial
Prospective, Single-arm, Phase II Clinical Study of Tirellizumab Combined With Carboplatin and Paclitaxel Polymer Micelles Neoadjuvant Therapy for cN+ Head and Neck Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2026-12-30
Drug
PD-1 monoclonal antibody
Product
Polymeric Micellar Paclitaxel
Clinical trial
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Status: Active (not recruiting), Estimated PCD: 2023-09-05
Clinical trial
Phase 2 Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2023-06-01
Product
IPI-549
Clinical trial
Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients
Status: Completed, Estimated PCD: 2007-06-01
Drug
Gemcitabine
Product
Pemetrexed
Clinical trial
Phase II Study of Nimotuzumab (TheraCim-hR3) Concurrent With Cisplatin/Radiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Completed, Estimated PCD: 2019-09-03
Drug
Nimotuzumab
Clinical trial
A Phase II Trial Aiming to Evaluate the Clinical Interest of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6
Status: Completed, Estimated PCD: 2022-11-05
Product
Abemaciclib
Clinical trial
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
Status: Active (not recruiting), Estimated PCD: 2019-07-01
Drug
Lurbinectedin
Clinical trial
Phase II Study of C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2009-07-01
Clinical trial
An Open Label Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
Status: , Estimated PCD: 2024-12-01
Clinical trial
Alternating Treatment Plans for Participants With Advanced Thoracic/Head & Neck Cancers (ATATcH)
Status: Recruiting, Estimated PCD: 2025-05-01
Product
5Fluorouracil
Clinical trial
A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-03-20
Product
18F-FSPG
Product
11C-Glutamine
Clinical trial
Phase II Investigation of Adjuvant Combined Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2021-04-16
Clinical trial
A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2028-02-01
Product
ALE.C04
Drug
Trastuzumab
Product
Keytruda
Clinical trial
A Phase II Clinical Trial of Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer Patients (CTMS# 20-0147)
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A Phase II/III Trial of Comparison of Benefit of Administration of Checkpoint Inhibitors Plus Chemodrug Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2033-11-01
Clinical trial
Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase Ib Study of Multivalent Autophagosome Vaccine, With or Without GITR Agonist, With Sequenced Checkpoint Inhibition (Anti-PD-1) - Immunotherapy Trio in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Product
INCAGN01876
Product
INCMGA00012
Clinical trial
A Randomized Phase I/II Trial of TheraT® Vectors Expressing HPV16 Specific Antigens in Combination With Neoadjuvant Chemotherapy Followed by Transoral Robotic Surgery or Risk/Response Stratified Chemoradiotherapy for Locoregional HPV16+ Oropharyngeal Cancer
Status: Recruiting, Estimated PCD: 2026-01-01
Drug
HB-201
Drug
HB-202
Clinical trial
A Phase II Study of Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-03-01
Product
Tadalafil
Product
DPV-001
Clinical trial
An Open-label, Non-randomized, Multi-arm, Phase II Trial to Evaluate the Efficacy of Pembrolizumab Combined With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Active (not recruiting), Estimated PCD: 2023-11-19
Clinical trial
Phase III Randomized Study With Cisplatinum and Conventional or Adaptive High Dose Radiotherapy for Advanced Head and Neck Cancer
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): "The APA Trial".
Status: Active (not recruiting), Estimated PCD: 2019-12-12
Product
nab-Paclitaxel
Clinical trial
Pilot, Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer: a Single-center, Single-arm, Phase II Clinical Trial
Status: Recruiting, Estimated PCD: 2024-10-30
Product
Penicillamine
Clinical trial
A Phase II Randomized Trial, Non Comparative, Evaluating Chemotherapy Associated Cisplatin, 5-fluorouracil and Docetaxel at Adapted Doses in Patients With Locally Advanced Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Drug
5-FU
Clinical trial
Phase II Evaluation of Cetuximab (C225) Combined With Induction Paclitaxel and Carboplatin Followed by C225, Paclitaxel, Carboplatin, and Radiation for Stage III/IV Operable Squamous Cancer of the Head and Neck
Status: Completed, Estimated PCD: 2010-02-01
Product
TSC-200-A0201
Product
TSC-204
Product
TSC-204-C0702 + TSC-203-A0201
Clinical trial
INVERT - Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy
Status: Not yet recruiting, Estimated PCD: 2028-07-01
Product
ENI using IMRT